<b>Conclusions</b>: When classified by the status of EGFR, ALK and HER2, early-stage NSCLC patients with HER2 alterations had significantly better DFS and OS than those with triple-negative biomarkers. This evidence concerns the gene EGFR and non-small cell lung carcinoma.